Allakos Inc. (NASDAQ:ALLK – Get Rating)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $7.15, but opened at $7.44. Allakos shares last traded at $7.29, with a volume of 7,101 shares.
Allakos Trading Up 0.3 %
The stock has a 50 day simple moving average of $7.45 and a 200-day simple moving average of $5.61. The firm has a market cap of $634.77 million, a P/E ratio of -1.10 and a beta of 0.51.
Allakos (NASDAQ:ALLK – Get Rating) last released its quarterly earnings data on Monday, November 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.25. As a group, equities analysts forecast that Allakos Inc. will post -5.18 earnings per share for the current fiscal year.
Institutional Trading of Allakos
Allakos Company Profile
Allakos Inc, a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.
- Get a free copy of the StockNews.com research report on Allakos (ALLK)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.